XELLIA PHARMACEUTICALS ApS: Financial statements 2023
CVR: 61094628
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,986,816,000 and a net result of DKK -2,384,901,000 compared with DKK -371,486,000 the year before. That is a decrease of 11.5% compared with the year before. The profit margin was -120%. Equity in the 2023 report amounted to DKK -597,775,000. The company had 650 employees in the financial year.
- Revenue
- DKK 1,986,816,000
- Gross Profit
- DKK -640,209,000
- Profit/Loss
- DKK -2,384,901,000
- Equity
- DKK -597,775,000
- Total Assets
- DKK 2,105,002,000
- Employees
- 650
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 2B | -640.2M | -2.4B | -597.8M | 650 |
| 2022 | 2.2B | 318.4M | -371.5M | 1.8B | 648 |
| 2021 | 1.8B | -47M | -503.1M | 2.1B | 640 |
| 2020 | 2B | 361.3M | -115.7M | 2.6B | 624 |
| 2019 | 2.3B | 873.5M | 390.7M | 1.4B | 623 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 1, 2023, John Ramsay Stewart has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of October 1, 2023, Michael Kocher has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of October 1, 2023, Geelanie Rodriguez Briones has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of October 1, 2023, Carl-Åke Carlsson has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of October 1, 2023, Michael Kocher is registered as director of XELLIA PHARMACEUTICALS ApS.
As of October 1, 2023, Carl-Åke Carlsson has stepped down as director of XELLIA PHARMACEUTICALS ApS.
XELLIA PHARMACEUTICALS ApS has published its annual report for 2022. Revenue came to DKK 2,245,303,000, and the net result was DKK -371,486,000.
As of February 28, 2023, Gisli Lukas Ihlemann Lundahl has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of February 6, 2023, Geelanie Rodriguez Briones has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of February 6, 2023, Niels Murmann has left the board of directors of XELLIA PHARMACEUTICALS ApS.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.
